# Neuromuscular Neurology Consultation

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Wilma Mankiller (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ML052-SYN-TD
- Date: 1980-03-23
- Fictional facility: St. Posthumous Health Center
- Fictional author: Marcus Okafor-Delaney, MD
- Calendar frame: true historical dates (modern content is anachronistic)

> True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

- Requested by: Rena Hawkfeather-Lindqvist, MD

## Reason for consultation

Woman of 34 with six weeks of fluctuating ptosis, diplopia and fatigable weakness of the arms, neck, chewing and voice, while recovering from a severe car crash last year: suspected generalized myasthenia gravis. Please confirm the diagnosis and advise on treatment, thymectomy and safety. **S**

## History

Ms. Mankiller is seen at the request of Dr. Hawkfeather-Lindqvist for six weeks of drooping eyelids, double vision by evening, tiring of the arms when brushing her hair, a tired jaw while eating, and a nasal voice after long conversations. Pyridostigmine 30 mg three times daily has helped her eyelids for a few hours after each dose, with mild cramps. She has had no breathlessness, choking or weak cough. She is recovering from a head-on car crash last year with fractures of both legs, ribs and face and many operations, and walks with a cane on rough ground. She has hereditary polycystic kidney disease with normal kidney function. She works for the Cherokee Nation and lives in rural Adair County. She wants to understand each treatment before agreeing to it, and to have blood tests near home. **S**

## Examination

| System | Finding |
|---|---|
| Eyes | Left ptosis after 40 seconds of upgaze; diplopia on sustained right gaze; pupils normal |
| Bulbar | Speech becomes nasal after counting to 40; jaw closure strong at rest |
| Neurological | Neck flexion 4 of 5; deltoids fatigue after 45 seconds of arm abduction; reflexes and sensation normal |
| Respiratory | Single-breath count to 30; FVC 3.25 L; negative inspiratory force -68 cm H2O |

BP 124/80 mmHg; pulse 76 bpm; respirations 16/min; temperature 36.6 °C; oxygen saturation 98% on room air; weight 61.6 kg; BMI 23.2 kg/m². All vital signs are synthetic.

## Data reviewed

Acetylcholine receptor binding antibodies 6.8 nmol/L (positive), drawn at the first visit; CT of the chest with contrast five days ago (residual thymic tissue for age, no thymoma, healed right rib fractures); kidney ultrasound five days ago (enlarged polycystic kidneys, height-adjusted total kidney volume 364 mL/m, Mayo Imaging Class 1B; small liver cysts); first-visit blood count, chemistry, TSH 1.9 mIU/L, hemoglobin A1c, urine albumin, FVC and negative inspiratory force; and repetitive nerve stimulation done today (3 Hz: 22 percent decrement in the nasalis, 18 percent in the trapezius, with partial repair after exercise). Acetylcholine receptor binding antibody: 6.8 nmol/L (high); Forced vital capacity (seated): 3.25 L; PHQ-2: 1. All results are synthetic.

## Assessment

1. **Generalized myasthenia gravis, AChR antibody positive, MGFA class IIa, MG-ADL 7, without thymoma** (G70.00). The diagnosis is confirmed by a positive antibody and a reproducible decrement on nerve stimulation; MuSK antibodies and single-fiber EMG are not needed. The weakness is mild to moderate and mainly ocular and limb, with mild bulbar involvement. Breathing measurements are normal, and there is no sign of impending crisis. **S**
2. **Immunotherapy** (Z79.52). Pyridostigmine alone is unlikely to control generalized disease. Prednisone is the first immunotherapy; starting at 10 mg and raising it by 10 mg a week to 40 mg lowers the risk of the early worsening that high starting doses can cause. A steroid-sparing agent is advised from the start because she is likely to need treatment for years. Azathioprine suits a woman of childbearing age better than mycophenolate, which must be avoided in pregnancy; it needs TPMT activity first, hepatitis B and tuberculosis screening, and regular blood counts and liver tests. Polycystic kidney disease with normal function does not change these doses. Pneumococcal and recombinant zoster vaccines should be given before immunosuppression, and live vaccines avoided. **S**
3. **Thymectomy**. In non-thymomatous AChR antibody-positive generalized MG between 18 and 50, thymectomy early in the disease improves outcomes and lowers immunotherapy needs (MGTX). It is elective and should be done once she is stable. Her healed rib fractures do not prevent a robotic approach from the right; she should see thoracic surgery in about four weeks, with surgery once prednisone has taken effect, about two to three months from now. **S**
4. **Newer targeted therapies**. Efgartigimod, an FcRn blocker, and the complement inhibitors eculizumab and ravulizumab work well in AChR antibody-positive generalized MG, but the guidance places complement inhibitors after other immunotherapies have failed, and her disease is not refractory. They are kept in reserve. A complement inhibitor would need meningococcal vaccination first. **S**
5. **Safety, medicines to avoid and kidney considerations** (Q61.2). Fluoroquinolones, aminoglycosides, macrolides, telithromycin, magnesium by vein, beta-blockers and neuromuscular blocking drugs can worsen MG; statins and iodinated contrast need caution. Her kidney function is normal, so drug doses and contrast are not limited by it, but NSAIDs should be avoided for her kidneys and a beta-blocker should not be chosen if her blood pressure ever needs treatment. **S**

## Recommendations

1. Pyridostigmine 60 mg four times daily while awake, 30 to 45 minutes before meals.
2. Prednisone 10 mg each morning, raised by 10 mg each week to 40 mg, held until after thymectomy, then tapered by 5 mg every two to three weeks toward 7.5 mg or less.
3. Azathioprine once TPMT activity is normal and hepatitis B and tuberculosis screening are negative: 50 mg daily, 100 mg after two weeks, then about 2 to 3 mg/kg (150 mg); blood count and liver tests every one to two weeks for two months, then every three months.
4. Calcium and vitamin D, DXA within the first months, and trimethoprim-sulfamethoxazole three times a week while prednisone is 20 mg or more with azathioprine.
5. PCV20 and recombinant zoster vaccine today, before immunosuppression; inactivated vaccines only from now on.
6. Thoracic surgery assessment in about four weeks for robotic extended thymectomy once she is stable.
7. Efgartigimod or a complement inhibitor only if she does not respond to, or cannot tolerate, standard immunotherapy.
8. A wallet card listing the medicines to avoid; same-day emergency care for breathlessness lying flat, a weak cough, choking or slurred speech, with FVC and negative inspiratory force measured at every visit while she is weak.
9. Discuss any planned pregnancy with neuromuscular neurology first.

## Strengths and supports

- Engagement in care and meaningful activity **S**

## Communication

Discussed with Dr. Hawkfeather-Lindqvist today. The plan was explained to Ms. Mankiller step by step, with time for her questions, and she agreed to it. Blood tests will be drawn at a Cherokee Nation Health Services clinic near her home where possible, with results sent to both clinics. She will decide whether and how her own Cherokee medicine is part of her care, and will tell us of any plant medicine so that interactions can be checked. **S**

## Follow-up

Nurse telephone call in one week as prednisone rises. Thoracic surgery assessment in about four weeks. Neuromuscular neurology review after thymectomy and every three months. Primary care follows her strength, breathing, glucocorticoid and azathioprine safety, and her kidney care at each visit. **S**

## Guideline basis

- Narayanaswami P, et al. International Consensus Guidance for Management of Myasthenia Gravis: 2020 Update. Neurology 2021;96(3):114-122 (2020), Myasthenia Gravis Foundation of America task force (Neurology)
- Sanders DB, et al. International consensus guidance for management of myasthenia gravis: Executive summary. Neurology 2016;87(4):419-425 (2016), Myasthenia Gravis Foundation of America task force (Neurology)
- Wolfe GI, et al. Randomized Trial of Thymectomy in Myasthenia Gravis (MGTX). N Engl J Med 2016;375(6):511-522 (2016), New England Journal of Medicine
- Howard JF Jr, et al. Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT). Lancet Neurol 2021;20(7):526-536 (2021), The Lancet Neurology
- Cautionary Drugs (medicines that may worsen myasthenia gravis) (2026), Myasthenia Gravis Foundation of America
- KDIGO 2025 Clinical Practice Guideline for the Evaluation, Management, and Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD). Kidney Int 2025;107(2S):S1-S239 (2025), Kidney Disease: Improving Global Outcomes (KDIGO)
- Humphrey MB, et al. 2022 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis. Arthritis Rheumatol 2023;75(12):2088-2102 (2022), American College of Rheumatology
